Prescient Therapeutics Ltd has released a press release.
PTX Opens First U.S. Site for PTX-100 Phase 2a Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- Prescient Therapeutics Extends Share Purchase Plan
- Prescient Therapeutics Opens Share Purchase Plan
- Prescient Therapeutics Launches Share Purchase Plan for $7m
- First Patient dosed for PTX-100 Phase 2a Study
- March 2025 Quarterly Update and Appendix 4C
Later from Prescient Therapeutics
- Prescient Therapeutics - Extension of Share Purchase Plan
- Trading Halt
- Prescient announces results of SPP & Launches Placement
- June 2025 Quarterly Update and Appendix 4C
- Prescient successfully completes $3 million Placement
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics